These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats. Wess G, Daisenberger P, Mahling M, Hirschberger J, Hartmann K. Vet Clin Pathol; 2011 Jun; 40(2):237-44. PubMed ID: 21434959 [Abstract] [Full Text] [Related]
4. Prevalence of the MYBPC3-A31P mutation in a large European feline population and association with hypertrophic cardiomyopathy in the Maine Coon breed. Mary J, Chetboul V, Sampedrano CC, Abitbol M, Gouni V, Trehiou-Sechi E, Tissier R, Queney G, Pouchelon JL, Thomas A. J Vet Cardiol; 2010 Dec; 12(3):155-61. PubMed ID: 21051304 [Abstract] [Full Text] [Related]
5. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. Lalor SM, Connolly DJ, Elliott J, Syme HM. J Vet Cardiol; 2009 May; 11 Suppl 1():S71-9. PubMed ID: 19398225 [Abstract] [Full Text] [Related]
6. Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test. Hanås S, Holst BS, Höglund K, Häggström J, Tidholm A, Ljungvall I. J Vet Intern Med; 2020 May; 34(3):1187-1197. PubMed ID: 32200578 [Abstract] [Full Text] [Related]
10. Genotype-phenotype correlation between the cardiac myosin binding protein C mutation A31P and hypertrophic cardiomyopathy in a cohort of Maine Coon cats: a longitudinal study. Granström S, Godiksen MT, Christiansen M, Pipper CB, Martinussen T, Møgelvang R, Søgaard P, Willesen JL, Koch J. J Vet Cardiol; 2015 Dec; 17 Suppl 1():S268-81. PubMed ID: 26776585 [Abstract] [Full Text] [Related]
12. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats. Fox PR, Rush JE, Reynolds CA, Defrancesco TC, Keene BW, Atkins CE, Gordon SG, Schober KE, Bonagura JD, Stepien RL, Kellihan HB, Macdonald KA, Lehmkuhl LB, Nguyenba TP, Sydney Moise N, Lefbom BK, Hogan DF, Oyama MA. J Vet Intern Med; 2011 Dec; 25(5):1010-6. PubMed ID: 21985136 [Abstract] [Full Text] [Related]
13. Multi-centered investigation of a point-of-care NT-proBNP ELISA assay to detect moderate to severe occult (pre-clinical) feline heart disease in cats referred for cardiac evaluation. Machen MC, Oyama MA, Gordon SG, Rush JE, Achen SE, Stepien RL, Fox PR, Saunders AB, Cunningham SM, Lee PM, Kellihan HB. J Vet Cardiol; 2014 Dec; 16(4):245-55. PubMed ID: 25456274 [Abstract] [Full Text] [Related]
14. Athlete's heart or hypertrophic cardiomyopathy: usefulness of N-terminal pro-brain natriuretic peptide. Godon P, Griffet V, Vinsonneau U, Caignault JR, Prevosto JM, Quiniou G, Guerard S. Int J Cardiol; 2009 Sep 11; 137(1):72-4. PubMed ID: 18676044 [Abstract] [Full Text] [Related]
16. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. Connolly DJ, Soares Magalhaes RJ, Fuentes VL, Boswood A, Cole G, Boag A, Syme HM. J Vet Cardiol; 2009 May 11; 11 Suppl 1():S41-50. PubMed ID: 19394286 [Abstract] [Full Text] [Related]
20. Investigation of an N-Terminal Prohormone of Brain Natriuretic Peptide Point-of-Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease. Harris AN, Beatty SS, Estrada AH, Winter B, Bohannon M, Sosa I, Hanscom J, Mainville CA, Gallagher AE. J Vet Intern Med; 2017 Jul 11; 31(4):994-999. PubMed ID: 28617995 [Abstract] [Full Text] [Related] Page: [Next] [New Search]